During the last session, Scilex Holding Company (NASDAQ:SCLX)’s traded shares were 0.65 million, with the beta value of the company hitting 1.08. At the end of the trading day, the stock’s price was $0.24, reflecting an intraday loss of -2.01% or -$0.01. The 52-week high for the SCLX share is $2.30, that puts it down -858.33 from that peak though still a striking 12.5% gain since the share price plummeted to a 52-week low of $0.21. The company’s market capitalization is $59.19M, and the average intraday trading volume over the past 10 days was 0.94 million shares, and the average trade volume was 1.38 million shares over the past three months.
Scilex Holding Company (SCLX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SCLX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
Scilex Holding Company (NASDAQ:SCLX) trade information
Scilex Holding Company (SCLX) registered a -2.01% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.01% in intraday trading to $0.24, hitting a weekly high. The stock’s 5-day price performance is -13.14%, and it has moved by 6.71% in 30 days. Based on these gigs, the overall price performance for the year is -83.89%. The short interest in Scilex Holding Company (NASDAQ:SCLX) is 6.05 million shares and it means that shorts have 3.93 day(s) to cover.
Scilex Holding Company (SCLX) estimates and forecasts
In the rating firms’ projections, revenue will increase 21.75% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.31M as predicted by 2 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 25.88M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 13.46M and 10.88M respectively. In this case, analysts expect current quarter sales to grow by 13.72% and then jump by 137.75% in the coming quarter.
While earnings are projected to return 121.38% in 2025.
SCLX Dividends
Scilex Holding Company is due to release its next quarterly earnings on 2025-Jan-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Scilex Holding Company (NASDAQ:SCLX)’s Major holders
Scilex Holding Company insiders own 25.93% of total outstanding shares while institutional holders control 20.34%, with the float percentage being 27.46%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 155.0 institutions own stock in it. As of 2024-06-30, the company held over 11.95 million shares (or 9.9428% of all shares), a total value of $23.06 million in shares.
The next largest institutional holding, with 6.71 million shares, is of BLACKROCK INC.’s that is approximately 5.5809% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.95 million.
Also, the Mutual Funds coming in first place with the largest holdings of Scilex Holding Company (SCLX) shares are SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Feb 28, 2025 indicates that SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF owns about 5.94 shares. This amounts to just over 2.44 percent of the company’s overall shares, with a $1.44 million market value. The same data shows that the other fund manager holds slightly less at 3.71, or about 1.53% of the stock, which is worth about $0.9 million.
